Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

BioMarin presents five-year data on Pompe disease treatment

BioMarin presents five-year data on Pompe disease treatment

BioMarin Pharmaceutical Inc., a company listed on NASDAQ under the ticker symbol BMRN, recently unveiled findings from a five-year study on POMBILITI and OPFOLDA treatments for late-onset Pompe disease. This information was shared during the World Muscle Society Congress held in Hiroshima, Japan. The PROPEL open-label extension study involved 82 participants, who all received continuous treatment from the beginning up to the fifth year.

On average, these individuals had been on prior treatments for about 7.6 years before starting this study. Of the 62 participants who had experienced enzyme replacement therapy (ERT) before, there was a slight improvement of 0.7% in the six-minute walk distance compared to their baseline. In contrast, the 20 participants who were ERT-naive saw a more significant improvement of 10.5% in the six-minute walk distance at the 4.5-year mark.

Similarly, the ERT-experienced group showed a decrease of 2.8% in the percent predicted forced vital capacity, while the ERT-naive group experienced a larger decrease of 4.4%. Side effects related to treatment were experienced by 51.2% of the participants, with five individuals deciding to discontinue the treatment due to safety concerns.

Two serious treatment-related adverse events were reported, comprising one case of chills and hypoxia, and another anaphylactoid reaction. BioMarin also presented Phase 1/2 data on an investigational treatment called nivudirsen (BMN 351) for Duchenne muscular dystrophy in boys aged 4 to 10 who have an exon 51 skipping. The 351-201 study indicated that this treatment was generally well tolerated.

POMBILITI combined with OPFOLDA is currently approved for treating adult patients with late-onset Pompe disease who weigh at least 40 kg and are not improving on current enzyme replacement therapy. This treatment comes with warnings about hypersensitivity reactions and is contraindicated in pregnancy. Late-onset Pompe disease is characterized by a deficiency of the enzyme acid alpha-glucosidase, leading to the accumulation of glycogen and progressive muscle weakness.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Health & Medicine

More from Friday 2 October →